Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors

British Journal of Cancer

Volumn 107, Issue 9, 2012, Pages 1454-1458

  Berghoff, A S ^a,b   Bago Horvath, Z ^b,c   Ilhan Mutlu, A ^b,c   Magerle, M ^b,c   Dieckmann, K ^b,c   Marosi, C ^b,c   Birner, P ^b,c   Widhalm, G ^b,c   Steger, G G ^b,c   Zielinski, C C ^b,c   Bartsch, R ^b,c   Preusser, M ^b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Austrian Breast and Colorectal Cancer Study Group   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

brain metastases; brain only metastatic behaviour; breast cancer subtypes; metastatic breast cancer; overall survival; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT INFORMATION; PRIORITY JOURNAL; PROBABILITY; STATISTICAL ANALYSIS; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL RATE; SURVIVORS;

EID: 84867898852     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.440     Document Type: Article

References (21)

1. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG (2012) Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 106(1): 25-31
2. Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, Rudas M, Mader RM, Poetter R, Zielinski CC, Steger GG (2007) Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 85(3): 311-317
3. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12): 2972-2977
4. Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106(3): 440-446
5. Boogerd W, Hart AA, Tjahja IS (1997) Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer. J Neurooncol 35(2): 161-167
6. Boogerd W, Vos VW, Hart AA, Baris G (1993) Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 15(2): 165-174
7. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM (2012) Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 118(19): 4652-4659
8. De Vita F, Giuliani F, Silvestris N, Rossetti S, Pizzolorusso A, Santabarbara G, Galizia G, Colucci G, Ciardiello F, Orditura M (2012) Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets 16(Suppl 2): S29-S34
9. Fidler IJ (2011) The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21(2): 107-112
10. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16): 2784-2795
11. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20): 3271-3277
12. Kiely BE, Soon YY, Tattersall MH, Stockler MR (2011) How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29(4): 456-463
13. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17): 3608-3617
14. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26(12): 1993-1999
15. Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, Michiara M, Silini EM, Ardizzoni A (2011) Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 117(9): 1837-1846
16. Niwinska A, Pogoda K, Murawska M, Niwinski P (2011) Factors influencing survival in patients with breast cancer and single or solitary brain metastasis. Eur J Surg Oncol 37(7): 635-642
17. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17(6): 935-944
18. Pfannschmidt J, Dienemann H (2010) Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer 69(3): 251-258
19. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4): 419-425
20. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167(4): 913-920
21. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1): 118-145